Seasonal allergy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Sat, 20 Jun 2026 04:04:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Seasonal allergy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness and Safety of a Grass and Olive Pollen Allergy Vaccine for Patients with Allergic Rhinitis or Asthma https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-olive-pollen-allergy-vaccine-for-patients-with-allergic-rhinitis-or-asthma/ Fri, 05 Jun 2026 10:52:54 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-olive-pollen-allergy-vaccine-for-patients-with-allergic-rhinitis-or-asthma/ This clinical trial is focused on studying the effectiveness and safety of a new treatment for people with allergic rhinitis or rhinoconjunctivitis, which are conditions that cause symptoms like sneezing, runny nose, and itchy eyes. These conditions can occur with or without mild to moderate asthma, a condition that affects breathing. The treatment being tested is a vaccine made from a mixture of modified allergen extracts from six types of grasses and olive pollen, known by the code name MG01_T517. The purpose of the study is to evaluate how well this vaccine works when given as an injection under the skin compared to a placebo.

Participants in the study will receive injections of either the vaccine or a placebo over a period of up to 12 months. The study will monitor the participants’ symptoms and any medication they use during the grass and olive tree pollen season, which typically occurs in April, May, and June. The study will also look at the number of days participants are free from symptoms and medication, any worsening of asthma symptoms, and overall quality of life related to rhinitis. Additionally, the study will assess the safety of the vaccine by tracking any side effects or reactions at the injection site.

The trial aims to provide valuable information on whether the vaccine can help reduce symptoms and improve the quality of life for people with allergies to grasses and olive trees. By comparing the vaccine to a placebo, researchers hope to determine its effectiveness in managing these allergic conditions. The study will also gather data on various health measures, including levels of specific antibodies in the blood, to better understand the vaccine’s impact on the immune system.

]]> Short‑course sublingual ITULAZAX birch pollen extract with Lactobacillus rhamnosus GG for patients with pollen‑associated food allergy https://clinicaltrials.eu/trial/short-course-sublingual-itulazax-birch-pollen-extract-with-lactobacillus-rhamnosus-gg-for-patients-with-pollen-associated-food-allergy/ Sun, 31 May 2026 04:02:45 +0000 https://clinicaltrials.eu/trial/short-course-sublingual-itulazax-birch-pollen-extract-with-lactobacillus-rhamnosus-gg-for-patients-with-pollen-associated-food-allergy/ People who are allergic to birch pollen often develop a related reaction to certain foods, especially apples; this is known as Pollen-associated Food Allergy. The underlying trigger is a sensitivity to birch pollen, called Birch pollen Allergy. The trial tests a new treatment that delivers small amounts of birch pollen extract under the tongue (sublingual administration) to help the immune system become less reactive. The product being studied is named ITULAZAX, and it is compared with an inactive substance, referred to as placebo.

The purpose of the study is to determine whether a short‑course of this sublingual therapy can lessen the symptoms that appear after eating a controlled amount of apple, known as an apple challenge. Participants will be randomly assigned to receive either the active drops or the inactive drops for several weeks, then they will attend a series of visits where they will eat the test apple and report any itching, stinging, or other reactions. Throughout the study, safety checks such as physical examinations and basic lab tests will be performed, and any side effects will be recorded.

]]> Study to Find the Best Dose of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis, with or without Asthma https://clinicaltrials.eu/trial/study-to-find-the-best-dose-of-beltavac-with-grass-pollen-extract-for-patients-with-allergic-rhinoconjunctivitis-with-or-without-asthma/ Mon, 04 May 2026 08:03:07 +0000 https://clinicaltrials.eu/trial/study-to-find-the-best-dose-of-beltavac-with-grass-pollen-extract-for-patients-with-allergic-rhinoconjunctivitis-with-or-without-asthma/ This clinical trial is focused on studying the treatment of allergic rhinoconjunctivitis, which is a condition that causes symptoms like sneezing, runny nose, and itchy eyes due to exposure to grass pollen. The study also includes patients who have asthma along with allergic rhinoconjunctivitis. The treatment being tested is called Beltavac, which is a mixture of grass pollen extracts that have been specially prepared to help reduce allergic reactions. The trial will compare the effects of Beltavac with a placebo to determine the best dose for treating these symptoms.

The purpose of the study is to find the optimal dose of Beltavac for treating allergic rhinoconjunctivitis. Participants in the study will receive injections of either Beltavac or a placebo over a period of 24 weeks. The injections are given under the skin, a method known as subcutaneous injection. Throughout the study, participants will have regular visits to monitor their symptoms and any changes in their condition. The study will also involve tests to measure the body’s response to the treatment, such as checking levels of specific antibodies in the blood.

By the end of the study, researchers aim to see if the treatment with Beltavac can reduce the sensitivity to grass pollen, as measured by a test called the Conjunctival Provocation Test. This test involves exposing the eye to a small amount of allergen to see if it causes a reaction. The study will also look at changes in certain blood markers related to allergies. The results will help determine if Beltavac is effective in reducing symptoms of allergic rhinoconjunctivitis and if it can be a useful treatment option for patients with this condition.

]]> Dose-finding study of sublingual immunotherapy with phleum pratense extract (vs sodium chloride) in patients with grass pollen allergic rhinitis https://clinicaltrials.eu/trial/dose-finding-study-of-sublingual-immunotherapy-with-phleum-pratense-extract-vs-sodium-chloride-in-patients-with-grass-pollen-allergic-rhinitis/ Wed, 29 Apr 2026 15:09:56 +0000 https://clinicaltrials.eu/trial/dose-finding-study-of-sublingual-immunotherapy-with-phleum-pratense-extract-vs-sodium-chloride-in-patients-with-grass-pollen-allergic-rhinitis/ The study focuses on Allergic rhinitis caused by grass pollen, a condition that produces sneezing, runny nose, itchy eyes and throat. The treatment being tested is a sublingual (under‑the‑tongue) spray containing the grass pollen extract phleum pratense at three different strengths: Vacuna Phleum pratense 1000 TBU/ml, Vacuna Phleum pratense 3000 TBU/ml and Vacuna Phleum pratense 6000 TBU/ml. A matching Placebo spray containing only sodium chloride is also used for comparison. The purpose of the trial is to find the dose that works best without compromising safety.

Participants will receive the assigned spray daily for a set period, while regular visits will include a simple nose test (nasal provocation test) to see how the nose reacts, and a quick breathing measurement called Nasal Inspiratory Peak Flow. Blood samples will be taken at the start and at the end to check levels of antibodies such as IgE and IgG4. Throughout the study, any side effects will be recorded, and standard rescue medicines may be used if needed. The overall length of involvement is several months, with regular check‑ins to monitor health and response.

]]> Study of CLU-RX-PHL injection therapy for patients with moderate to severe grass pollen allergy to find the most effective and safe dose https://clinicaltrials.eu/trial/study-of-clu-rx-phl-injection-therapy-for-patients-with-moderate-to-severe-grass-pollen-allergy-to-find-the-most-effective-and-safe-dose/ Wed, 29 Apr 2026 15:06:30 +0000 https://clinicaltrials.eu/trial/study-of-clu-rx-phl-injection-therapy-for-patients-with-moderate-to-severe-grass-pollen-allergy-to-find-the-most-effective-and-safe-dose/ This study focuses on treating patients with allergic rhinitis and rhinoconjunctivitis caused by grass pollen. These conditions cause symptoms like nasal congestion, runny nose, and eye irritation during grass pollen season. The study will test a medication called CLU-RX-PHL, which contains modified grass pollen extract and is given as an subcutaneous injection under the skin. This type of treatment is known as allergy immunotherapy, which helps reduce allergic reactions to specific substances.

The purpose of this study is to determine which dose level of CLU-RX-PHL works best and is best tolerated by patients. The study will compare three different strengths of CLU-RX-PHL (high, medium, and low dose) against a placebo. The treatment will be given over a period of 50 weeks.

During the study, participants will receive injections of either CLU-RX-PHL or placebo. The effectiveness of the treatment will be measured during the grass pollen season by tracking allergy symptoms and the use of additional allergy medications. Participants will need to keep track of their symptoms using an electronic diary. The study team will monitor participants’ health throughout the treatment period to ensure safety.

]]> Study of sublingual immunotherapy with Phleum pratense pollen extract spray in patients with moderate to severe grass pollen allergic rhinitis https://clinicaltrials.eu/trial/study-of-sublingual-immunotherapy-with-phleum-pratense-pollen-extract-spray-in-patients-with-moderate-to-severe-grass-pollen-allergic-rhinitis/ Wed, 29 Apr 2026 15:06:30 +0000 https://clinicaltrials.eu/trial/study-of-sublingual-immunotherapy-with-phleum-pratense-pollen-extract-spray-in-patients-with-moderate-to-severe-grass-pollen-allergic-rhinitis/ This clinical trial focuses on testing a treatment for allergic rhinitis and rhinoconjunctivitis caused by grass pollen allergy. These conditions cause symptoms like nasal congestion, runny nose, and eye irritation during grass pollen season. The study will test a medication called SLI-RX-PHL, which contains Phleum pratense pollen extract and is given as a spray under the tongue.

The purpose of the study is to determine how well different doses of SLI-RX-PHL work and how safe they are for treating grass pollen allergies. The treatment will be tested in three different strengths (low, medium, and high dose), and some participants will receive a placebo. The medication or placebo will be given as a spray that is applied under the tongue.

The study will take place during grass pollen season, when allergy symptoms are typically most severe. Participants will need to keep a daily record of their allergy symptoms and any additional medications they need to take for symptom relief. The treatment period will last up to 50 weeks, during which the effectiveness of the medication will be measured by tracking how well it reduces allergy symptoms and the need for additional relief medications.

]]> Study of sublingual birch pollen extract (SLI-RX-BET) in different doses for patients with moderate to severe allergic rhinitis caused by birch pollen https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-immunotherapy-with-birch-pollen-extract-for-patients-with-moderate-to-severe-birch-pollen-allergy/ Wed, 29 Apr 2026 15:05:03 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-immunotherapy-with-birch-pollen-extract-for-patients-with-moderate-to-severe-birch-pollen-allergy/ This clinical trial focuses on treating patients with allergic rhinitis and rhinoconjunctivitis caused by birch pollen. These conditions cause symptoms like nasal congestion, runny nose, and eye irritation during birch pollen season. The study tests a medication called SLI-RX-BET, which is given as a spray under the tongue (sublingual spray) and contains birch pollen extract.

The purpose of this study is to find the most effective and safest dose of SLI-RX-BET for treating birch pollen allergies. The medication will be tested in three different strengths (low, medium, and high dose), and some participants will receive a placebo. The treatment involves daily use of the spray for approximately 10 months.

During the study, participants will need to track their allergy symptoms and use of additional medications during the birch pollen season. The treatment is specifically designed for people who have experienced moderate to severe allergic symptoms from birch pollen for at least two years. The medication aims to help reduce allergy symptoms and decrease the need for other allergy medications.

]]> Study of CLU-RX-BET injection therapy for patients with moderate to severe birch pollen allergies https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-clu-rx-bet-for-patients-with-moderate-to-severe-birch-pollen-allergy/ Wed, 29 Apr 2026 15:04:24 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-clu-rx-bet-for-patients-with-moderate-to-severe-birch-pollen-allergy/ This study focuses on allergic rhinitis and rhinoconjunctivitis caused by birch pollen allergy. These conditions cause symptoms like nasal congestion, runny nose, and eye irritation during birch pollen season. The study will test a medication called CLU-RX-BET, which is given as an injection under the skin to treat birch pollen allergies. The purpose is to find the most effective and best-tolerated dose of this treatment.

The study will compare three different doses of CLU-RX-BET (high, medium, and low) against a placebo. The treatment will be given through subcutaneous injections, which means the medication is injected beneath the skin. The study medication contains modified birch pollen extract that has been treated with a substance called glutaraldehyde to make it safer for treatment.

During the study, participants will receive multiple injections over a period of 50 weeks. They will need to track their allergy symptoms and use of additional medications during the birch pollen season. The effectiveness of the treatment will be measured by monitoring how well it reduces allergy symptoms and the need for other allergy medications compared to the placebo treatment.

]]> Study on the Effectiveness and Safety of CLU-RX-DPT for Patients with Moderate-to-Severe House Dust Mite Allergy https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-clu-rx-dpt-for-patients-with-moderate-to-severe-house-dust-mite-allergy/ Wed, 29 Apr 2026 15:04:04 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-clu-rx-dpt-for-patients-with-moderate-to-severe-house-dust-mite-allergy/ This clinical trial is focused on studying a condition known as allergic rhinitis, which is a type of allergy that affects the nose and eyes, often caused by house dust mites. The study aims to evaluate a treatment called subcutaneous cluster-immunotherapy, which involves injecting small doses of an allergen to help the body build up a tolerance. The treatment being tested is called CLU-RX-DPT, which comes in three different doses: low, mid, and high. These doses contain a modified form of the allergen from house dust mites, specifically Dermatophagoides pteronyssinus, which is a common cause of dust mite allergies.

The purpose of the study is to find the most effective and best-tolerated dose of CLU-RX-DPT for people with moderate-to-severe allergic rhinitis due to house dust mites. Participants in the study will receive either one of the doses of CLU-RX-DPT or a placebo, which looks and feels like the treatment but does not contain the active allergen. The study will monitor how well the treatment works in reducing allergy symptoms and the need for other allergy medications over a period of time.

Throughout the study, participants will be asked to keep track of their symptoms and any allergy medications they use. This information will help researchers understand how the treatment affects daily life and overall comfort. The study will also look at how the treatment impacts the quality of life for those with allergic rhinitis. The goal is to determine which dose of CLU-RX-DPT provides the best balance of benefits and side effects for managing symptoms of house dust mite allergies.

]]> Study on the Effectiveness and Safety of a Grass and Juniperus Oxycedrus Allergy Vaccine for Patients with Allergic Rhinitis or Rhinoconjunctivitis with or without Mild Asthma https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-juniperus-oxycedrus-allergy-vaccine-for-patients-with-allergic-rhinitis-or-rhinoconjunctivitis-with-or-without-mild-asthma/ Wed, 29 Apr 2026 15:00:37 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-a-grass-and-juniperus-oxycedrus-allergy-vaccine-for-patients-with-allergic-rhinitis-or-rhinoconjunctivitis-with-or-without-mild-asthma/ This clinical trial is focused on studying the effectiveness and safety of a new treatment for people with allergic rhinitis or rhinoconjunctivitis, which are conditions that cause symptoms like sneezing, runny nose, and itchy eyes. These conditions may occur with or without mild to moderate asthma, a condition that affects breathing. The treatment being tested is a vaccine made from a mixture of modified allergen extracts from six types of grasses and a plant called Juniperus oxycedrus. This vaccine is given as an injection under the skin. The study will compare the effects of this vaccine to a placebo, which looks like the treatment but does not contain any active ingredients.

The purpose of the study is to evaluate how well the vaccine works in reducing symptoms and the need for medication during the pollen seasons of grasses and cupressaceae, which are types of plants that can cause allergies. Participants will receive the vaccine or placebo over a period of 12 months. Throughout the study, participants will be monitored for any changes in their symptoms, the number of days they are symptom-free, and any asthma flare-ups. The study will also assess the overall safety of the vaccine by tracking any side effects or reactions at the injection site.

Participants will be asked to record their symptoms and medication use using a smartphone app. The study will also measure certain immune system markers, such as total IgE and specific IgG4, which are types of antibodies related to allergies. Additionally, the study will evaluate the participants’ quality of life and asthma control using questionnaires. The trial aims to provide valuable information on whether this new vaccine can help people with grass and cupressaceae allergies manage their symptoms more effectively.

]]> Study on the Effectiveness of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis and Possible Asthma https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-beltavac-with-grass-pollen-extract-for-patients-with-allergic-rhinoconjunctivitis-and-possible-asthma/ Wed, 29 Apr 2026 14:28:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-beltavac-with-grass-pollen-extract-for-patients-with-allergic-rhinoconjunctivitis-and-possible-asthma/ This clinical trial is focused on studying the effects of a treatment called Beltavac, which is a mixture of grass pollen extracts, on patients who suffer from allergic rhinoconjunctivitis. This condition is commonly known as hay fever and is caused by an allergic reaction to pollen, leading to symptoms like a runny nose, sneezing, and itchy eyes. Some patients in the study may also have asthma, a condition that affects the airways and can cause breathing difficulties.

The purpose of the study is to determine the best dose of Beltavac for treating allergic rhinoconjunctivitis. Participants will receive the treatment through injections under the skin, known as subcutaneous injections. The study will compare the effects of Beltavac with a placebo, which is an inactive substance, to see how well the treatment works. The study will last for about 24 weeks, during which participants will have regular visits to monitor their symptoms and any changes in their condition.

Throughout the study, participants will be asked to keep a diary using a special app to record their symptoms and any medication they take. This will help researchers understand how the treatment affects their daily lives, especially during the peak pollen season when symptoms are usually at their worst. The study aims to find out if Beltavac can reduce the severity of symptoms and improve the quality of life for people with allergic rhinoconjunctivitis and asthma.

]]> Study on the Effectiveness and Safety of Allergenic Extract of Olea Europaea Pollen for Patients with Moderate-to-Severe Olive Pollen Allergy https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-allergenic-extract-of-olea-europaea-pollen-for-patients-with-moderate-to-severe-olive-pollen-allergy/ Wed, 29 Apr 2026 14:27:25 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-allergenic-extract-of-olea-europaea-pollen-for-patients-with-moderate-to-severe-olive-pollen-allergy/ This clinical trial is focused on studying the effects of a treatment for people who have been suffering from moderate-to-severe allergic rhinitis or rhinoconjunctivitis due to olive pollen for at least two years. The treatment being tested is called CLU-RX-OLE, which is a type of immunotherapy given through injections. The study aims to find the most effective and well-tolerated dose of this treatment. Participants in the study will receive either the CLU-RX-OLE treatment or a placebo, which looks like the treatment but does not contain the active ingredient.

During the study, participants will be monitored to see how their symptoms change over time. The study will compare the symptoms and medication use of those receiving the active treatment with those receiving the placebo. This will help determine the treatment’s effectiveness in reducing symptoms and improving the quality of life for those with olive pollen allergies. The study will also assess the safety and any side effects of the treatment.

The trial will take place over a period of time, with participants being asked to keep track of their symptoms and any medications they use. This information will be used to evaluate the treatment’s impact on their condition. The goal is to find a balance between the benefits and any potential risks of the treatment, ensuring it is both effective and safe for patients with olive pollen allergies.

]]> Study on the Effectiveness and Safety of Phleum Pratense Pollen Extract for Patients with Moderate-to-Severe Grass Pollen Allergy https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-phleum-pratense-pollen-extract-for-patients-with-moderate-to-severe-grass-pollen-allergy/ Wed, 29 Apr 2026 14:26:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-phleum-pratense-pollen-extract-for-patients-with-moderate-to-severe-grass-pollen-allergy/ This clinical trial is focused on studying the effectiveness and safety of a treatment for people who have been suffering from moderate-to-severe allergic rhinitis or rhinoconjunctivitis due to grass pollen for at least two years. The treatment being tested is called SULGEN® Spray Phleum pratense, which is a type of sublingual immunotherapy. This means the treatment is administered as a spray under the tongue. The study aims to find the most effective and well-tolerated dose of this spray, balancing its benefits and risks.

Participants in the study will receive either the SULGEN® Spray Phleum pratense or a placebo, which looks and tastes like the real treatment but does not contain the active ingredient. The study will compare the effects of the treatment and the placebo on symptoms and the need for additional medication during the peak grass pollen period. The study will also look at how the treatment affects the quality of life and the number of days participants experience no symptoms or severe symptoms.

The trial will involve regular assessments to monitor the participants’ symptoms and any changes in their condition. This includes using a nasal provocation test, which involves exposing the nose to the allergen to see how it reacts. The study is expected to run until October 2025, with recruitment starting in November 2023. The goal is to provide valuable information on how well the SULGEN® Spray Phleum pratense works for people with grass pollen allergies.

]]> Study on the Effects of Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis https://clinicaltrials.eu/trial/study-on-the-effects-of-mannan-conjugated-birch-pollen-allergoids-for-adolescents-and-adults-with-birch-pollen-induced-allergic-rhinitis-or-rhinoconjunctivitis/ Wed, 29 Apr 2026 14:22:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-mannan-conjugated-birch-pollen-allergoids-for-adolescents-and-adults-with-birch-pollen-induced-allergic-rhinitis-or-rhinoconjunctivitis/ This clinical trial is focused on studying the effects of a new treatment for people with birch pollen-induced allergic rhinitis or rhinoconjunctivitis. These conditions are commonly known as hay fever, where exposure to birch pollen causes symptoms like sneezing, runny nose, and itchy eyes. The treatment being tested is called T502, which is a special type of vaccine made from birch pollen. It is given as an injection under the skin.

The purpose of the study is to see how well the T502 treatment works in reducing allergy symptoms and the need for other allergy medications during the peak birch pollen season. Participants in the study will receive either the T502 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will compare the symptoms and medication use between those receiving the actual treatment and those receiving the placebo.

Participants will be involved in the study for a period that includes the peak birch pollen season. During this time, they will receive regular injections and will be monitored for any changes in their allergy symptoms. The study aims to provide valuable information on the effectiveness of T502 in managing symptoms of birch pollen allergies.

]]>